A Phase I Dose Escalation Study, With Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients With Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 05 Aug 2017
At a glance
- Drugs AbGn 107 (Primary)
- Indications Colorectal cancer; Gastric cancer; Pancreatic cancer
- Focus Adverse reactions; Proof of concept
- Sponsors AbGenomics Corporation
- 04 May 2017 Planned End Date changed from 1 Mar 2019 to 1 Jul 2019.
- 04 May 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Apr 2019.
- 04 May 2017 Status changed from not yet recruiting to recruiting.